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Self controlled case series methods: an alternative to standard 
epidemiological study designs
Irene Petersen,1 ,2 Ian Douglas,3 Heather Whitaker4 
The self controlled case series (SCCS) 
method is an epidemiological study 
design for which individuals act as their 
own control—ie, comparisons are 
made within individuals. Hence, only 
individuals who have experienced an 
event are included and all time 
invariant confounding is eliminated. 
The temporal association between a 
transient exposure and an event is 
estimated. SCCS was originally 
developed for evaluation of vaccine 
safety, but has since been applied in a 
range of settings where exact 
information on the size of the 
population at risk is lacking or 
identification of an appropriate 
comparison group is difficult—eg, for 
studies of adverse effects of drug 
treatments. We provide an overview of 
the SCCS method, with examples of its 
use, discuss limitations, assumptions, 
and potential biases that can arise 
where assumptions are not met, and 
provide solutions and examples of 
good practice.
In 1951, Richard Doll and Austin Bradford Hill wrote to 
all registered doctors in the United Kingdom to obtain 
information about their smoking habits. This research 
was groundbreaking as they were one of the first teams 
to demonstrate a link between smoking and various 
 diseases.1  Since then, epidemiological study designs, 
such as cohort and case-control studies, have been 
widely applied in medical research (see supplementary 
web table w1). There are several situations, however, 
where standard epidemiological study designs fall 
short. For example, in the research of adverse effects of 
vaccines it can be difficult to identify suitable compari-
son groups (eg, if most of the population receives the 
vaccine). Likewise, studies on hospital data may not 
have information on the exact catchment areas and 
hence it is a struggle to find suitable controls for cases 
of a particular event. In these situations the self con-
trolled case series (SCCS) method provides an alterna-
tive epidemiological study design to investigate the 
association between a transient exposure and an out-
come event. The SCCS method is a case only method; it 
has the advantages that no separate controls are 
required and any fixed confounder is automatically 
controlled for.2 3
In this paper we provide an overview of SCCS meth-
odology and some examples of how the method has 
been applied, in order to give an idea of the potentials 
of SCCS. As for any epidemiological study design, the 
SCCS method has some assumptions. We discuss these 
and identify the key limitations and potential biases.
SCCS method
The SCCS method aims to estimate a relative incidence, 
which compares the incidence of adverse events within 
periods of hypothesised excess risk due to exposure 
with incidence during all other times. Asking “when?” 
rather than “who?” becomes the key question. Precise 
timings are needed, so the SCCS method is best suited 
to acute events and transient exposures for which peri-
ods of exposure risk can be clearly defined. Only those 
who have experienced an event (cases) can contribute 
any information on when the event occurred, so only 
data on these individuals need to be collected.
Having identified cases, the next step in setting up the 
data for SCCS is to define observation periods—these are 
the study periods for each individual, over which a full 
history on the timing of events and exposures are avail-
able. The third step is to define the periods when expo-
sure may have had an impact within the observation 
period, eg, a fixed number of days after receipt of a first 
drug prescription or a vaccine; these are known as expo-
sure risk periods. All remaining time within the observa-
tion period constitutes baseline exposure periods, to 
which the exposure risk periods will be compared. Stud-
ies using SCCS might include multiple exposure risk 
periods as it may be necessary to capture either multiple 
doses or varying exposure related risk using several risk 
periods (which may be of the same or different lengths). 
Observation periods can be further divided according to 
age groups or seasons, or any other relevant time 
Summary pointS
The self controlled case series (SCCS) method provides an alternative to 
established epidemiological designs
SCCS is best suited to acute recurrent or non-recurrent events and transient 
exposures for which precise timings are available
Estimation is within individuals and no separate controls are required, hence the 
method is self controlled, and time invariant factors are cancelled out
Follow-up is not censored at the event, so when events can impact on subsequent 
exposure, care must be taken to ensure analyses are carried out that eliminate or 
minimise bias
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 varying factors so they can be accounted for in the anal-
ysis. The fourth step is to “map” events in relation to the 
different periods identified. Once the data are set up, the 
final step is to estimate the relative incidence of events in 
prespecified exposure risk periods compared with 
 baseline periods, while taking into account the effect of 
any time varying confounders such as age groups 
(see  supplementary file).
In figure 1 we illustrate the SCCS set up for someone 
with two exposure risk periods and five age groups 
(panel A) and use this individual to illustrate the output 
of an SCCS model (panels B to D).
Comparisons are not made between individuals as in 
a cohort or case-control study; estimation is within 
individuals. Any factor or characteristic that remains 
constant over observation periods cancels out of the 
SCCS model; this includes individual specific underly-
ing risk and factors such as sex, ethnicity, and depriva-
tion. It is in this sense that the SCCS model is self 
controlled.
Conceptually, the SCCS method builds on the princi-
ples of a cohort study (see supplementary file). Individ-
uals are followed through time, the exposure history is 
fixed, and events are random. However, the SCCS 
method differs in that the total number of events occur-
ring within an individual’s observation period is fixed 
and follow-up is not censored at an event. Hence all 
exposures occurring within the observation period—
both before and after individuals have experienced the 
event—are included in the analysis.
A worked example that illustrates how to fit the SCCS 
model is included in the supplementary materials, and 
further details of the theory and model fitting are given 
in Whitaker et al.3  Below we present two examples of 
studies that applied the SCCS method. Figure 2 provides 
a schematic overview of the SCCS study design for each 
of the studies, and the key results.
Example applications of the SCCS method in medical 
research
Example 1: a possible drug interaction between 
clopidogrel and proton pump inhibitors
Douglas et al used both a cohort and an SCCS approach 
to study a drug interaction between clopidogrel and 
proton pump inhibitors on the risk of myocardial 
infarction.4  The cohort analysis found an increased 
risk of myocardial infarction when clopidogrel was 
combined with a proton pump inhibitor, supporting 
the notion that an interaction between the two drugs 
would reduce the effectiveness of clopidogrel (relative 
incidence 1.30, 95% confidence interval 1.12 to 1.50). 
However, the effect was non-specific, as an increased 
risk of death from non-vascular causes was also seen, 
suggesting it was difficult to account for underlying 
confounding. The SCCS analysis examined whether 
the risk of myocardial infarction was increased in the 
period when the proton pump inhibitor was added to 
clopidogrel treatment (fig  2). Thus the observation 
period was the duration of clopidogrel treatment, and 
the exposure risk periods were periods of proton pump 
inhibitor treatment, which varied in length and num-
ber among the study participants. SCCS found no 
increased risk for myocardial infarction (0.75, 0.55 to 
1.01), suggesting that the underlying confounding had 
been dealt with through this design.
Example 2: inflammations and myocardial infarction 
or stroke
Smeeth et  al aimed to evaluate the association 
between inflammation and myocardial infarction or 
stroke.5  The exposures included inflammatory stimuli: 
vaccinations and acute infection. SCCS was used 
because of concerns that people receiving vaccina-
tions may differ from those who were unvaccinated, 
and likewise,  people acquiring infections may differ 
from uninfected people in ways that are difficult to 
measure and account for. Exposure risk periods were 
defined up to 91 days after the recording of either an 
infection or a vaccination and were further subdivided 
to allow the relative incidence of events to vary over 
this period (fig 2 ). An increased risk of both myocar-
dial infarction and stroke was seen over the risk period 
after either a  systemic respiratory tract infection or a 
urinary tract infection, with the strongest effect in the 
first seven days. The risk was still increased up to 91 
days, but appeared to be returning towards baseline. 
No increased risk was seen after influenza, tetanus, or 
pneumococcal vaccinations.5 Figure 2 provides the 
incidence rate ratios for myocardial infarction after 
respiratory tract infections.
A
Period
Exposure risk status
Age group
B
Age related
relative incidence
C
Exposure related
relative incidence
D
Overall prole of
relative incidence
on each period
1
0
0
1
1
1
2
2
3.6
2.7
1.5
1.5
1.8 1.8
1.2
1.2
2.2
0.9 0.5
0.5
2
0
1
3
1
1
4
1
2
5
0
2
6
0
3
7
1
3
8
1
4
9
0
4
Fig 1 | Illustration of SCCS model output using a hypothetical individual with two exposure 
risk periods and five age groups. (Panel A) An individual observation period segmented by 
two exposure risk periods (red boxes, labelled exposure risk status 1) and five age groups 
(blue boxes, labelled 0 to 4). Baseline categories for age and exposure are labelled age 
group 0 and exposure risk status 0, respectively. (Panel B) Exposure related relative 
incidences. Note for the baseline category the relative incidence is 1 and the exposure 
relative incidence is arbitrarily set to 1.8. (Panel C) Age related relative incidence on age 
groups 1-4 compared with age group 0. The age relative incidences for age groups 1-4 have 
been set to 2, 1.5, 1.2, and 0.5, respectively. (Panel D) Overall profile of relative incidence 
on each of the nine intervals; this is the age related relative incidence multiplied by the 
exposure related relative incidence
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SCCS assumptions
As for other epidemiological study designs, the SCCS 
model makes certain assumptions that should be met 
to provide valid and unbiased estimates. Below we 
outline these assumptions. Table 1 provides a sum-
mary of assumption violations that can arise, and the 
solutions and examples of good practice against 
each.
Occurrence of an event should not (appreciably) 
affect subsequent exposures
A key assumption is that subsequent exposures should 
not appreciably be affected by previous events. How-
ever, this may often be the case. For example, occur-
rence of an event may delay exposure, the event may be 
a contraindication for treatment, or the event may 
result in or is death. This assumption also means that 
the event itself should not determine the timing of the 
end of the observation period.
Ignoring this assumption may potentially produce 
biased estimates, but there are various extensions or 
moderations to the SCCS method that can mitigate 
potential biases (table 1). Note that independent causes 
of death or end of observation do not cause bias.
Temporary delay or increase in exposure after an 
event
If the event only temporarily delays exposure this will 
result in a deficit of events in the period just before 
exposure that reduces the overall incidence in the base-
line period. This results in relative incidence estimates 
that are biased upwards. One way to correct for this bias 
is to include a “pre-exposure period” (table 1 ) just 
before an exposure.3  A pre-exposure period can simi-
larly be applied if there is a short term increase in the 
probability of exposure after an event (table 1 ), which 
would otherwise bias estimates towards the null. A 
pre-exposure period was included in the clopidogrel 
and proton pump inhibitor interaction example, antici-
pating that the chance of starting treatment with a pro-
ton pump inhibitor could be temporarily altered by 
having a myocardial infarction (fig 2 ).4 The pre-expo-
sure period “trick” only works for short term delay (in 
relation to the length of observation). If there is a long 
Start PPI
Start clopidogrel
A Clopidogrel and PPI interaction
2 week pre-exposure period
PPI exposure risk period
(variable length)
Age 67 years
Age 69 years
Age 68 years
Stop PPI
1st evidence of
stopping clopidogrel
Start PPI Stop PPI
Infection or vaccination
6 months
aer patient
registered
in database
B Inflammation and myocardial infarction
4-7
8-14
15-28
29-91
Post infection risk period (days)
1-3
Age 55-59 years
Age 50-54 yearsEnd of
patient record
Baseline
Pre-exposure (14 days)
PPI exposure period
Myocardial infarction
375
10
395
Incidence rate ratio (95% CI)
1.00
1.39 (0.71 to 2.70)
0.75 (0.55 to 1.01)
Period
Headline SCCS results from clopidogrel and PPI. From Douglas et al 20124
Baseline
1-3 days post infection
4-7 days post infection
8-14 days post infection
15-28 days post infection
29-91 days post infection
Events
17 099
322
276
422
576
1658
Incidence rate ratio (95% CI)
1.00
4.95 (4.45 to 5.53)
3.20 (2.84 to 3.60)
2.81 (2.54 to 3.09)
1.95 (1.79 to 2.12)
1.40 (1.33 to 1.48)
Period
Headline SCCS results for systemic respiratory tract infection from Inflammation and 
Myocardial Infarction Study. From Smeeth et al 20045
Fig 2 | Typical observation periods, risk periods, and headline results for two examples of applied SCCS. PPI=proton pump 
inhibitor
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term delay in exposure after events, the methods in the 
next paragraph may be applied.
No exposure can occur after the event, eg, if the 
outcome is death
If the outcome is death, then exposures that might have 
otherwise occurred after the event will never be known. 
This is also true if the exposure history is only collected 
up until the time of the event or if the event is a contra-
indication to exposure (table 1 ). If a fixed length expo-
sure can only occur once, a simple solution is to define 
the observation to begin with the start of exposure and 
finish with the end of study that would have applied 
had death or censoring not occurred.3 8  This a priori 
definition of the observation period means that only 
exposed cases are included, and if the exposure risk 
period is of a fixed length then the full exposure history 
is always known even beyond the time of death or cen-
soring. Alternatively, there is an extension of the SCCS 
method that produces unbiased estimates given these 
scenarios.9
If the outcome is death, but the exposure is external 
to the case and fully observable after death—eg, a 
weather phenomenon—the standard SCCS method can 
be applied using the full planned observation period, 
had the case not died.
Event increases the probability of death
If the event carries high mortality, such as myocardial 
infarction or stroke, then there is a chance that obser-
vation periods could be cut short as a direct result of 
the event. Resulting bias can be in either direction 
(table 1 ). If the event mortality is low, bias will be neg-
ligible and the situation ignorable. Comparison of 
results from fitting SCCS models to all cases and 
excluding those who died can be made; major differ-
ences would suggest bias. Bias may be corrected by fit-
ting an extension that involves modelling post-event 
survival times.12
Event rates are constant within intervals
Event rates are assumed to be constant within each 
defined period. While such an assumption is often 
unrealistic, it is convenient, makes relative incidence 
estimates easy to interpret, and is commonly used in 
other study designs. Control of strong age or season 
effects is important and SCCS models with greater flex-
ibility have been developed.14 15
Events must be independently recurrent or rare
The SCCS method was developed for independent 
recurrent events, but it has been demonstrated that the 
method is valid for non-recurrent events when the risk 
of occurrence over the study period in the entire cohort 
is 10% or less.12  A test for independence has been devel-
oped.16  If events are dependent, a simple solution is to 
study just first events (table 1 ). Alternatively, an exten-
sion that allows a first event to increase the future event 
risk may be used17
Final remarks
With this paper we have sought to demonstrate how 
the SCCS method provides an alternative to standard 
epidemiological designs when investigating associa-
tions between a transient exposure and an outcome 
event. A major strength of the SCCS is that it is self 
controlled and accounts for any factor or characteris-
tic that remains constant over the observation period. 
Thus, where uncertainty over the control of fixed con-
founders exists in a cohort or case-control study, 
SCCS may provide a superior design, given careful 
thought is made to applying the methodology 
 correctly.
Linked information
The Open University hosts a website for the SCCS methodology, with example datasets 
and code for analysis in Stata, SAS, R, Genstat, and GLIM (http://statistics.open.ac.uk/sccs)
A link to the tutorial by Whitaker et al3 can also be found at  http://statistics.open.ac.uk/
sccs/sccs.pdf
Table 1 | Violation of assumptions, impact, and solutions with examples of good practice
Problems Solutions Examples
Event temporarily decreases 
probability of exposure
Include a pre-exposure period Stowe et al studied the risk of infections after mumps, measles, and rubella vaccination. Vaccination 
is delayed when a child has an infection; a 14 day pre-exposure period was included to allow 
for this6
Event temporarily increases 
probability of exposure
Include a pre-exposure period Gibson et al studied the association between prescription drugs and motor vehicle crashes. 
A four week pre-exposure period was included as some drugs may be used to treat anxiety or 
pain caused by the crash7
No exposure can occur  
(or is observed) after event
For single exposures that cannot be 
repeated, begin observation period at 
exposure, so only exposed cases are 
included. End observation at planned end
Hubbard et al studied the association between first bupropion prescription and sudden death. 
The observation period began with date of first prescription and ended (beyond death) with 
date of last data collection for the cohort. At the time, bupropion could only be prescribed as a 
single course of treatment8
For single or multiple exposures, use 
method outlined in Farrington et al9
Dodd et al studied the association between influenza vaccination and Guillain Barré syndrome 
(GBS). Some practitioners will not vaccinate patients with previous GBS.10 Various analyses were 
performed: standard SCCS, vaccinated cases only, and the method outlined in Farrington et al9
Event increases probability 
of death
Undertake suitable tests or sensitivity 
analyses excluding cases who died as a 
result of event
Langan et al studied the risk of stroke after herpes zoster infection. A sensitivity analysis 
was performed excluding cases who died within 90 days of stroke. Findings were not 
modified11
If necessary, use methods outlined in 
Farrington et al12 to adjust for bias
Brauer et al studied the association between antipsychotic drugs and myocardial infarction 
using both methods outlined in Farrington et al12 and a standard SCCS analysis. There was 
little difference in results13
Recurrences of an event are 
not independent
Study first event only Recurrence of stroke is not independent of the first occurrence, so only a first stroke event can 
be studied. In a study on the risk of stroke, Langan et al began the observation period 12 
months into follow-up time to ensure first stroke events had been correctly identified11
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